Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × milademetan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Neoplasms 1 Mesothelioma 1 Melanoma 1 Lymphoma 1 Liposarcoma 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Trastuzumab 513 Paclitaxel 488 Cyclophosphamide 471 Docetaxel 417 Capecitabine 355 Letrozole 300 Fulvestrant 267 Doxorubicin 249 Carboplatin 234 Tamoxifen 223 Anastrozole 182 Radiotherapy 179 exemestane 176 Epirubicin 175 Bevacizumab 163 Lapatinib 149 Vinorelbine 146 Gemcitabine 144 pembrolizumab 142 pertuzumab 141 palbociclib 128 Exercise 114 Fluorouracil 103 Albumin-Bound Paclitaxel 103 Magnetic Resonance Spectroscopy 101 eribulin 97 130-nm albumin-bound paclitaxel 91 Everolimus 88 Taxes 83 Cisplatin 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡